MX2016007179A - Metodos para el tratamiento de canceres hematologicos, y el uso de biomarcadores como predictores de la sensibilidad clinica frente a las terapias inmunomoduladoras. - Google Patents

Metodos para el tratamiento de canceres hematologicos, y el uso de biomarcadores como predictores de la sensibilidad clinica frente a las terapias inmunomoduladoras.

Info

Publication number
MX2016007179A
MX2016007179A MX2016007179A MX2016007179A MX2016007179A MX 2016007179 A MX2016007179 A MX 2016007179A MX 2016007179 A MX2016007179 A MX 2016007179A MX 2016007179 A MX2016007179 A MX 2016007179A MX 2016007179 A MX2016007179 A MX 2016007179A
Authority
MX
Mexico
Prior art keywords
treatment
biomarkers
methods
predictors
clinical sensitivity
Prior art date
Application number
MX2016007179A
Other languages
English (en)
Spanish (es)
Inventor
William Burnell Trotter Matthew
Original Assignee
Celgene Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Celgene Corp filed Critical Celgene Corp
Publication of MX2016007179A publication Critical patent/MX2016007179A/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • A61K31/4523Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57557Immunoassay; Biospecific binding assay; Materials therefor for cancer of other specific parts of the body, e.g. brain
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/106Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/158Expression markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Health & Medical Sciences (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
MX2016007179A 2013-12-06 2014-12-05 Metodos para el tratamiento de canceres hematologicos, y el uso de biomarcadores como predictores de la sensibilidad clinica frente a las terapias inmunomoduladoras. MX2016007179A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361913046P 2013-12-06 2013-12-06
PCT/US2014/068767 WO2015085160A2 (en) 2013-12-06 2014-12-05 Methods for treating hematological cancers and the use of biomarkers as a predictor of clinical sensitivity to immunodulatory therapies

Publications (1)

Publication Number Publication Date
MX2016007179A true MX2016007179A (es) 2016-09-08

Family

ID=53274284

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2016007179A MX2016007179A (es) 2013-12-06 2014-12-05 Metodos para el tratamiento de canceres hematologicos, y el uso de biomarcadores como predictores de la sensibilidad clinica frente a las terapias inmunomoduladoras.

Country Status (12)

Country Link
US (1) US20160312292A1 (2)
EP (1) EP3077547A4 (2)
JP (1) JP2017503481A (2)
KR (1) KR20160090390A (2)
AU (1) AU2014360316A1 (2)
BR (1) BR112016012792A2 (2)
CA (1) CA2932266A1 (2)
EA (1) EA201691143A1 (2)
IL (1) IL245936A0 (2)
MX (1) MX2016007179A (2)
PH (1) PH12016501023A1 (2)
WO (1) WO2015085160A2 (2)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20160282354A1 (en) 2013-11-08 2016-09-29 The Broad Institute, Inc. Compositions and methods for selecting a treatment for b-cell neoplasias
WO2015085172A2 (en) 2013-12-06 2015-06-11 Celgene Corporation Methods for determining drug efficacy for the treatment of diffuse large b-cell lymphoma, multiple myeloma, and myeloid cancers
EP3996039A1 (en) * 2014-10-17 2022-05-11 Stichting Maastricht Radiation Oncology "Maastro-Clinic" Image analysis method supporting illness development prediction for a neoplasm in a human or animal body
WO2016196580A1 (en) 2015-06-02 2016-12-08 Celgene Corporation Methods for determining drug efficacy for treatment of cancer using ratios of cereblon associated proteins
WO2017044793A1 (en) 2015-09-11 2017-03-16 The Brigham And Women's Hospital, Inc. Methods of characterizing resistance to modulators of cereblon
WO2017053555A1 (en) * 2015-09-25 2017-03-30 Celgene Corporation Methods for treating diffuse large b-cell lymphoma and the use of biomarkers as a predictor of responsiveness to drugs
KR20180095094A (ko) 2016-01-08 2018-08-24 셀진 코포레이션 암을 치료하기 위한 방법 및 치료요법에 대한 임상 감수성의 예측변수로서 바이오마커의 용도
EP3674416A4 (en) * 2017-09-29 2021-05-26 Kyushu University, National University Corporation METHOD AND KIT FOR PREDICTING THE THERAPEUTIC EFFECTIVENESS OF CHEMOTHERAPY FOR PATIENTS WITH DIFFUSED LARGE B-CELL LYMPHOMA
IL292305A (en) * 2019-10-21 2022-06-01 Celgene Corp Methods for the treatment of hematological cancer and the use of associated biomarkers for 2-(2,6-deoxypyridin-3-yl)-4-((2-fluoro-4-((3-morpholinoazetidin-1-yl)methyl)benzyl)amino)isodonyl 1,3-discussion
WO2024258819A1 (en) * 2023-06-15 2024-12-19 The Broad Institute, Inc. Neoplastic cytotoxicity induced by glycosylation
FR3158743A1 (fr) * 2024-01-30 2025-08-01 Universite Grenoble Alpes Biomarqueurs et outil pronostique pour les patients atteint de lymphomes b diffus a grandes cellules

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009085234A2 (en) * 2007-12-20 2009-07-09 Signal Pharmaceuticals, Inc. Use of micro-rna as a biomarker of immunomodulatory drug activity
KR20130038838A (ko) * 2010-03-12 2013-04-18 셀진 코포레이션 레날리도미드, 및 예측 인자로서 유전자 및 단백질 바이오마커를 사용한 비호지킨 림프종의 치료 방법
AU2012249491B2 (en) * 2011-04-29 2016-12-15 Celgene Corporation Methods for the treatment of cancer and inflammatory diseases using cereblon as a predictor

Also Published As

Publication number Publication date
KR20160090390A (ko) 2016-07-29
US20160312292A1 (en) 2016-10-27
CA2932266A1 (en) 2015-06-11
WO2015085160A3 (en) 2015-07-30
PH12016501023A1 (en) 2016-07-04
JP2017503481A (ja) 2017-02-02
BR112016012792A2 (pt) 2017-08-08
IL245936A0 (en) 2016-07-31
EA201691143A1 (ru) 2016-11-30
EP3077547A2 (en) 2016-10-12
AU2014360316A1 (en) 2016-06-16
WO2015085160A2 (en) 2015-06-11
EP3077547A4 (en) 2017-11-08

Similar Documents

Publication Publication Date Title
MX2016007179A (es) Metodos para el tratamiento de canceres hematologicos, y el uso de biomarcadores como predictores de la sensibilidad clinica frente a las terapias inmunomoduladoras.
MX2014009256A (es) Dispositivos de recogida de muestras con agentes de estabilizacion sanguinea.
BR112015022496A2 (pt) dispositivo de limpeza de instrumento médico
SA521430032B1 (ar) Vista أجسام مضادة لـ وأجزاء منها
MX2015012437A (es) Esteroides neuroactivos, composiciones, y usos de los mismos.
MX2015012646A (es) Verificacion de ubicacion de factores multiples.
CL2015002978A1 (es) Uso de 2,3-dihidroimidazo[1,2-c]quinazolinas sustituidas
BR112017017886A2 (pt) gerando populações de células endoteliais arteriais
MX337507B (es) Metodo de intra - prediccion, y codificador y decodificador que lo utilizan.
BR112018003969A2 (pt) plataforma de aplicativo de célula pequena
BR112015006847A2 (pt) um elemento auxiliar de barbeamento ou depilação de contato com a pele que compreende ao menos uma substância sensibilizante termicamente resiliente
EA201591742A1 (ru) Способ улучшения диагностики заболеваний с использованием измеряемых аналитов
PE20161120A1 (es) Aparato y metodos de registro de hoyo
MY178540A (en) A surface feature manager
MX2016007903A (es) Metodos de elaboración de perfiles de epitopos de celulas t, elaboracion de composiciones de celulas t y tratamiento de enfermedades.
BR112015018696A2 (pt) rotulagem de padrão
BR112015017563A2 (pt) dispositivo de acesso vascular para inserção reprodutível de uma cânula para uma local de punção
CY1120220T1 (el) Μεθοδοι και κυτια για προσδιορισμο της καταστασης λοιμωξης απο φυματιωση
EA201401201A1 (ru) Способ
EP3457138A3 (en) Novel biomarkers for acute myeloid leukemia
MX2015007978A (es) Metodo y dispositivo para actualizacion de datos de documentos electronicos.
UY34858A (es) Compuestos de azetidina y piperidina útiles como inhibidores de pde10
MX2015008773A (es) Composiciones y metodos para tratar linfoma cutaneo de celulas t.
ES2493693B1 (es) Método para predecir o pronosticar la respuesta de un sujeto humano que padece un cáncer al tratamiento con un antagonista del receptor NK1
RU2011119752A (ru) Способ оценки безопасности введения наночастиц меди в организм